Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.

Feb 27, 2025 · British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's opposition...

5 days ago · GSK is fronting £38.5 million (nearly $50 million), in a partnership with South Korea’s ABL Bio to develop novel drugs for neurodegenerative diseases.. Aside from its upfront payment, GSK will also be on the hook for up to £2.075 billion ($2.66 billion) in research, development, regulatory and commercialization milestones, spread …

3 days ago · GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. Every breakthrough...

5 days ago · GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier.

1 day ago · GSK plc is a global biopharma company. The Companyâ s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma.

Oct 24, 2024 · GSK plc (LSE/NYSE: GSK) today announced its largest U.S. manufacturing investment to date. The up to $800 million investment will bring state-of-the-art drug substance manufacturing and additional drug product manufacturing capabilities to the company’s site in Marietta, Pennsylvania, along with over 200 new jobs.

GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma Regulatory designation based on promising early data in this rare bone cancer.

6 days ago · GSK is betting potentially billions of dollars that a smaller drug company’s technology can help create new treatments for brain-corroding diseases. Through a licensing deal announced Sunday, GSK has gained access to drug delivery technology from South Korea’s ABL Bio. This “Grabody-B” platform is designed to shuttle medicines across ...

5 days ago · GSK's clinical-stage pipeline is currently focused on oncology, respiratory, immunology and inflammation, and infectious diseases, including HIV, but the ABL deal and others signed in recent ...